Chr. Hansen ups outlook after strong Q3

Natural ingredients provider Chr. Hansen (OMX: CHR) has jumped in today’s trading on the heels of another strong quarter. The bioscience company serving food, nutritional, pharmaceutical and agricultural industries reported organic growth of 10% and EBIT growth of 19% in the first nine months of the financial year 2011/12. The momentum continued on Q3 across all divisions. The company raises its revenue growth outlook for the full year. The company now expects 9-11% (earlier 8-10%) organic growth excluding carmine price effect and an improved profitability with EBIT margin between 26.5%-27% (earlier above 26%). Adjusted for higher carmine raw material prices, revenue is expected to grow 6-8% (5-7%).